Cardiva Medical, Inc. Announces Appointment of Lisa Garrett, Chief Financial Officer and VP of Human Resources

Sunnyvale, CA., April 8, 2015 -- Cardiva Medical, Inc. announced today that Lisa Garrett has been appointed Chief Financial Officer and VP of Human Resources effective immediately. Ms. Garrett succeeds Mac Farnsworth, who has served as CFO since 2008.

“Lisa brings a tremendous depth of experience with all aspects of financial leadership at both large and emerging growth companies in the medical device space”, said John Russell, President and CEO of Cardiva. “She will be able to make an immediate contribution at Cardiva as we continue to expand commercial sales of the VASCADE next generation vascular closure device.”

Ms. Garrett brings over 20 years of diversified finance experience to Cardiva Medical, Inc. Most recently, Ms. Garrett had been the CFO and VP of Human Resources at Corventis, Inc, a wireless cardiac patient monitoring company that was acquired by Medtronic in 2014. Prior to Corventis, she was the Senior Director of Corporate Financial Planning and Analysis at Sybase. Ms. Garrett also spent seven years at Guidant Corporation, holding positions in Planning and Forecasting and Internal Audit while also leading a financial system implementation team. Prior to joining Guidant, Ms. Garrett worked at Eli Lilly and Company in a variety of financial roles, including Financial Planning and Corporate Treasury. Before entering the health care industry, she practiced as a CPA at Ernst and Young.

Ms. Garrett holds a BBS in Accounting, and an MBA from Indiana University.

About Cardiva Medical, Inc.

Cardiva Medical, Inc. is a medical device company that’s focused on developing and commercializing innovative vascular closure technology designed to help the body heal itself following catheterization. The Company’s products include VASCADE, a next generation extravascular closure system and Catalyst II and Catalyst III that are designed to aid manual compression. VASCADE was approved by the FDA in 2013 and approved for CE marking in 2012. Catalyst II and Catalyst III were cleared for marketing by the FDA in 2007 and 2009, respectively. For more information, go to

VASCADE® and Cardiva Catalyst® are registered trademarks of Cardiva Medical, Inc.